Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer

Journal of Urology

Volumn 166, Issue 1, 2001, Pages 93-99

  Ellis, William J ^a   Etzioni, Ruth ^a   Vessella, Robert L ^a   Hu, Chengcheng ^a   Goodman, Gary E ^a  

^a NONE

Author keywords

Diagnosis; Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 0034975963     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66084-3     Document Type: Article

References (27)

1. Asymptomatic incidence and duration of prostate cancer
2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
3. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
4. Diagnosis of prostatic carcinoma: The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasound
5. Morphometric and clinical studies on 68 consecutive radical prostatectomies
6. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
7. A complex between prostate specific antigen and alpha 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
8. Prostate specific antigen in serum occurs predominantly in complex with alpha-1 antichymotrypsin
9. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
10. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
11. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
12. Measurement of complexed PSA improves specificity for early detection of prostate cancer
13. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
14. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer
15. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
16. Models for longitudinal data: A generalized estimating equation approach
17. Random-effects models for longitudinal data
18. A marginal regression modelling framework for evaluating medical diagnostic tests
19. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
20. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old
21. Observations on the doubling time of prostate cancer: The use of serial prostate specific antigen in patients with untreated disease as a measure of increasing cancer volume
22. Prostate-specific antigen as predictor of prostate cancer in black men and white men
23. Two-year stability of free and total PSA in frozen serum samples
24. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
25. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
26. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer